Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Metrics to compare | ACTI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACTIPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.7x | −2.4x | −0.7x | |
PEG Ratio | −0.10 | −0.06 | 0.00 | |
Price/Book | 110.7x | 2.5x | 2.6x | |
Price / LTM Sales | - | 8.6x | 3.2x | |
Upside (Analyst Target) | 296.8% | 130.1% | 47.0% | |
Fair Value Upside | Unlock | 20.3% | 7.5% | Unlock |